NEW YORK, July 29, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Juno Therapeutics Inc. (NASDAQ: JUNO), Amicus
Therapeutics Inc. (NASDAQ: FOLD), ImmunoGen Inc. (NASDAQ: IMGN),
CEL-SCI Corporation (AMEX: CVM), and Ignyta Inc. (NASDAQ: RXDX).
Free research report on Juno Therapeutics can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=JUNO On
Tuesday, July 28, 2015, the NASDAQ
Composite ended at 5,089.21, up 0.98%, the Dow Jones Industrial
Average advanced 1.09%, to finish the day at 17,630.27, and the
S&P 500 closed at 2,093.25, up 1.24%. The gains were broad
based as all the sectors ended the session in positive. Register
for your complimentary reports at the links given below.
Juno Therapeutics Inc.'s stock advanced 1.72%, to close the day
at $48.62. The stock recorded a
trading volume of 1.40 million shares, below its three months
average volume of 2.19 million shares. Over the last one month and
over the past three months, Juno Therapeutics Inc.'s shares have
gained 4.31% and 2.79%, respectively. However, the stock has lost
6.89% since the start of this year. The company's shares are
trading 4.60% below their 200-day moving average. Additionally,
Juno Therapeutics Inc. has a Relative Strength Index (RSI) of
43.44. Sign up and read the free notes on JUNO at:
https://www.EquityResearchInstitute.com/reports?keyword=JUNO
On Tuesday, shares in Amicus Therapeutics Inc. recorded a
trading volume of 1.32 million shares, lower than their three
months average volume of 2.07 million shares. The stock ended the
day 4.37% higher at $16.48. Amicus
Therapeutics Inc.'s stock has surged 17.30% in the last one month,
54.60% in the previous three months and 98.08% on YTD basis. The
company is trading above its 50-day and 200-day moving averages by
20.83% and 67.34%, respectively. Furthermore, shares of Amicus
Therapeutics Inc. have an RSI of 65.04. The complimentary notes on
FOLD can be downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=FOLD
ImmunoGen Inc.'s stock gained 3.90%, to close Tuesday's session
at $18.10. The stock recorded a
trading volume of 0.67 million shares, below its three months
average volume of 1.97 million shares. Over the last one month and
previous three months, ImmunoGen Inc.'s shares have gained 28.55%
and 108.53%, respectively. Additionally, the stock has rallied
196.72% since the start of this year. The company is trading 28.67%
and 85.00% above its 50-day and 200-day moving averages,
respectively. Furthermore, ImmunoGen Inc.'s stock has an RSI of
65.40. Register for free on Equity Research Institute and access
the latest research on IMGN at:
https://www.EquityResearchInstitute.com/reports?keyword=IMGN
CEL-SCI Corp.'s stock finished Tuesday's session 13.29% higher
at $0.64. A total of 1.01 million
shares were traded, which was above its three months average volume
of 0.62 million shares. Over the last one month and since the
beginning of this year, CEL-SCI Corp.'s shares have advanced 8.47%
and 10.34%, respectively. However, the stock has declined 35.35% in
the previous three months. The company's shares are trading below
their 50-day and 200-day moving averages by 7.79% and 17.45%,
respectively. CEL-SCI Corp.'s stock has an RSI of 49.65. The
complete research on CVM is available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=CVM
On Tuesday, shares in Ignyta Inc. ended the session 1.28% higher
at $14.22. The stock reported a
trading volume of 0.40 million shares, below its three months
average volume of 0.61 million shares. Although, Ignyta Inc.'s
shares have lost 6.26% in the last one month, it has surged 63.07%
in the previous three months and 107.59% on YTD basis. The stock is
trading 50.95% above its 200-day moving average. Moreover, shares
of Ignyta Inc. have an RSI of 48.55. Free in-depth research on RXDX
is available at:
https://www.EquityResearchInstitute.com/reports?keyword=RXDX
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com